Clinical Trials Logo

Clinical Trial Summary

Primary Objective: Part A - To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score - To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B - To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives - To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients - To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05203380
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email [email protected]
Status Recruiting
Phase Phase 4
Start date January 27, 2022
Completion date August 12, 2024

See also
  Status Clinical Trial Phase
Completed NCT03054428 - Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT04893707 - The Study of CM310 in Patients With Atopic Dermatitis Phase 2
Active, not recruiting NCT03989349 - Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Active, not recruiting NCT03985943 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Recruiting NCT04921345 - Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04893941 - Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT04444752 - A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Withdrawn NCT05056779 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Phase 3
Completed NCT04805411 - Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 2
Recruiting NCT05186922 - The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis Phase 1/Phase 2
Recruiting NCT03057860 - TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
Recruiting NCT03989206 - Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT05017480 - A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Phase 2